Note: Descriptions are shown in the official language in which they were submitted.
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
TREATMENT OF ISCHEMIA
Cross-Reference to Priority Application
This application claims priority under U.S. and international law (including
but
not limited to the Paris Convention and 35 U.S.C. 119(e)) to U.S.
Provisional
Patent Application Serial No. 60/611,241 (US60/611,241), filed September 16,
2004,
which is incorporated herein by reference in its entirety for all purposes.
Government License Rights
This invention was made with U.S. Government support under grant R21
NS42799 from the National Institutes of Health. The U.S. Government thus may
have certain license rights in this invention.
Background
Strokes may be caused by a disruption of blood flow to the brain, for example,
due to a clot or a leak in a blood vessel that supplies the brain with blood.
This
disruption of blood flow deprives brain tissue of oxygen, often resulting in
localized
death of brain tissue (focal infarction) and thus permanent damage to the
brain.
Changes in the ion flux into neurons may lead to the cell death produced by
stroke. Accordingly, various ion channels may be candidates for mediating this
altered ion flux, thus confounding the search for a suitable therapeutic
target.
Summary
The present teachings provide a system, including methods and
compositions, for treatment of ischemia.
Brief Description of the Drawings
Figure 1 is a view of a flowchart illustrating an exemplary method of treating
ischemia, in accordance with aspects of the present teachings.
Figure 2 is a view of a flowchart illustrating an exemplary method of
identifying
drugs for treating ischemia, in accordance with aspects of the present
teachings.
Figure 3 is a series of graphs presenting exemplary data related to the
electrophysiology and pharmacology of acid sensing ion channel (ASIC) proteins
in
cultured mouse cortical neurons, in accordance with aspects of the present
teachings.
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
2
Figure 4 is an additional series of graphs presenting exemplary data related
to
the electrophysiology and pharmacology of ASIC proteins in cultured mouse
cortical
neurons, in accordance with aspects of the present teachings.
Figure 5 is a set of graphs and traces presenting exemplary data showing that
modeled ischemia may enhance activity of ASIC proteins, in accordance with
aspects of the present teachings.
Figures 6 and 7 are a set of graphs and traces presenting exemplary data
showing that ASIC proteins in cortical neurons may be Ca2+ permeable, and that
Ca2+ permeability may be ASIC1 a dependent, in accordance with aspects of the
present teachings.
Figure 8 is a series of graphs presenting exemplary data showing that acid
incubation may induce glutamate receptor-independent neuronal injury that is
protected by ASIC blockade, in accordance with aspects of the present
teachings.
Figure 9 is a series of graphs presenting exemplary data showing that ASIC1 a
may be involved in acid-induced injury in vitro, in accordance with aspects of
the
present teachings.
Figure 10 is a series of graphs with data showing neuroprotection in brain
ischemia in vivo by ASIC1 a blockade and by ASIC1 gene knockout, in accordance
with aspects of the present teachings.
Figure 11 is a graph plotting exemplary data for the percentage of ischemic
damage produced by stroke in an animal model system as a function of the time
and
type of treatment, in accordance with aspects of the present teachings.
Figure 12 is a view of the primary arnino acid sequence of an exemplary
cystine knot peptide, PcTxl, with various exemplary peptide features shown, in
accordance with aspects of the present teachings.
Figure 13 is a comparative view of the cystine knot peptide of Figure 12
aligned with various exemplary deletion derivatives of the peptide, in
accordance
with aspects of the present teachings.
Figure 14 is an exemplary graph plotting the amplitude of calcium current
measured in cells as a function of the ASIC family member(s) expressed in the
cells,
in accordance with aspects of the present teachings.
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
3
Figure 15 is a graph presenting exemplary data related to the efficacy of
nasally administered PcTx venom in reducing ischemic injury in an animal model
system, in accordance with aspects of the present teachings.
Detailed Description
The present teachings provide a system, including methods and
compositions, for treatment of ischemia. The methods may include approaches
for
reducing injury resulting from ischemia and/or for identifying drugs for
ischemia
treatment. The methods selectively may inhibit one or more members of the acid
sensing ion channel (ASIC) family, to provide a targeted therapy for ischemia
treatment.
Figure 1 shows a flowchart 20 with exemplary steps 22, 24 that may be
performed in a method of treating ischemia. The steps may be performed any
suitable number of times and in any suitable combination. In the method, an
ischemic subject (or subjects) may be selected for treatment, indicated at 22.
An
ASIC-selective inhibitor then may be administered to the ischemic subject(s),
indicated at 24. Administration of the inhibitor to the ischemic subject may
be in a
therapeutically effect amount, to reduce ischemia-induced injury to the
subject, for
example, reducing the amount of brain damage resulting from a stroke.
A potential explanation for the efficacy of the ischemia treatment of Figure 1
may be offered by the data of the present teachings (e.g., see Example 1). In
particular, the damaging effects of ischemia may not be equal to acidosis,
that is,
acidification of tissue/cells via ischemia may not be sufficient to produce
ischemia-
induced injury. Instead, ischemia-induced injury may be caused, in many cases,
by
calcium flux into cells mediated by a member(s) of the ASIC family,
particularly
ASIC1 a. Accordingly, selective inhibition of the channel activity of ASIC1 a
may
reduce this harmful calcium flux, thereby reducing ischemia-induced injury.
Figure 2 shows a flowchart 30 with exemplary steps 32, 34 that may be
performed in a method of identifying drugs for treatment of ischernia. The
steps may
be performed any suitable number of times and in any suitable combination. In
the
method, one or more ASIC-selective inhibitors may be obtained, indicated at
32. The
inhibitors then may be tested on an ischemic subject for an effect on ischemia-
induced injury, indicated at 34.
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
4
The methods of the present teachings may provide one or more advantages
over other methods of ischemia treatment. These advantages may include (1)
less
ischemia-induced injury, (2) fewer side effects of treatment (e.g., due to
selection of
a more specific therapeutic target), and/or (3) a longer time window for
effective
treatment, among others.
Further aspects of the present teachings are described in the following
sections, including (I) ischemia, (II) ischemic subjects and subject
selection, (III)
ASIC inhibitors, (IV) administration of inhibitors, (V) identification of
drugs, and (VI)
examples.
I. Ischemia
The system of the present teachings is directed to treatment of any suitable
ischemia. lschemia, as used herein, is a reduced blood flow to an organ(s)
and/or
tissue(s). The reduced blood flow may be caused by any suitable mechanism
including a partial or complete blockage (an obstruction), a narrowing (a
constriction), and/or a leak/rupture, among others, of one or more blood
vessels that
supply blood to the organ(s) and/or tissue(s). Accordingly, ischemia may be
created
by thrombosis, an embolism, atherosclerosis, hypertension, hemorrhage, an
aneurysm, surgery, trauma, medication, and/or the like. The reduced blood flow
thus
may be chronic, transient, acute, sporadic, and/or the like.
Any suitable organ or tissue may experience a reduced blood flow in the
ischemia being treated. Exemplary organs and/or tissues may include the brain,
arteries, the heart, intestines, the eye (e.g., the optic nerve), etc.
Ischemia-induced
injury (i.e., disease and/or damage) produced by various ischemias may include
ischemic myelopathy, ischemic optic neuropathy, ischemic colitis, coronary
heart
disease, and/or cardiac heart disease (e.g., angina, heart attack, etc.),
among
others. Ischemia-induced injury thus may damage and/or kill cells and/or
tissue, for
example, producing necrotic (infarcted) tissue, inflammation, and/or tissue
remodeling, among others, at affected sites within the body. Treatment
according to
aspects of the present teachings may reduce the incidence, extent, and/or
severity of
this injury.
The system of the present teachings may provide treatment of stroke. Stroke,
as used herein, is brain ischemia produced by a reduced blood supply to a part
(or
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
all) of the brain. Symptoms produced by stroke may be sudden (such as loss of
consciousness) or may have a gradual onset over hours or days. Furthermore,
the
stroke may be a major ischemic attack (a full stroke) or a more minor,
transient
ischemic attack, among ~ others. Symptoms produced by stroke may include, for
5 example, hemiparesis, hemiplegia, one-sided numbness, one-sided weakness,
one-
sided paralysis, temporary limb weakness, limb tingling, confusion, trouble
speaking,
trouble understanding speech, trouble seeing in one or both eyes, dim vision,
loss of
vision, trouble walking, dizziness, a tendency to fall, loss of coordination,
sudden
severe headache, noisy breathing, and/or loss of consciousness. Alternatively,
or in
addition, the symptoms may be detectable more readily or only via tests and/or
instruments, for example, an ischemia blood test (e.g., to test for altered'
albumin,
particular protein isoforms, damaged proteins, etc.), an electrocardiogram, an
electroencephalogram, an exercise stress test, and/or the like.
II. lschemic Subiects and Subiect Selection
The system of the present teachings may provide treatment of ischemic
subjects to reduce ischemic injury to the subjects. An ischemic subject, as
used
herein, is any person (a human subject) or animal (an animal subject) that has
ischemia, an ischemia-related condition, a history of ischemia, and/or a
significant
chance of developing ischemia after treatment begins and during a time period
in
which the treatment is still effective.
The ischemic subject may be an animal. The term "animal," as used herein,
refers to any animal that is not human. Exemplary animals that may be suitable
include any animal with a bloodstream, such as rodents (mice, rats, etc.),
dogs, cats,
birds, sheep, goats, non-human primates, etc. The animal may be treated for
its own
sake, e.g., for veterinary purposes (such as treatment of a pet).
Alternatively, the
animal may provide an animal model of ischemia, to facilitate testing drug
candidates
for human use, such as to determine the candidates' potency, window of
effectiveness, side effects, etc. Further aspects of testing performed with
animal
model systems are described below in Section V.
An ischemia-related condition may be -any consequence of ischemia. The
consequence may be substantially concurrent with the onset ischemia (e.g., a
direct
effect of the ischemia) and/or may occur substantially after ischemia onset
and/or
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
6
even after the ischemia is over (e.g., an indirect, downstream effect of the
ischemia,
such reperfusion of tissue when ischemia ends). Exemplary ischemia-related
conditions may include any combination of the symptoms (and/or conditions)
listed
above in Section I. Alternatively, or in addition, the symptoms may include
local
and/or systemic acidosis (pH decrease), hypoxia (oxygen decrease), free
radical
generation, and/or the like.
lschemic subjects for treatment may be selected by any suitable criteria.
Exemplary criteria may include any detectable symptoms of ischemia, a history
of
ischemia, an event that increases the risk of (or induces) ischemia (such as a
surgical procedure, trauma, administration of a medication, etc.), and/or the
like. A
history of ischemia may involve one or more prior ischemic episodes. In some
examples, a subject selected for treatment may have had an onset of ischemia
that
occurred at least about one, two, or three hours before treatment begins, or a
plurality of ischemic episodes (such as transient ischemic attacks) that
occurred less
than about one day, twelve hours, or six hours prior to initiation of
treatment.
III. ASIC Inhibitors
Inhibitors of ASIC family members, as used herein, are substances that
reduce (partially, substantially, or completely block) the activity or one or
more
members of the ASIC family, that is, ASIC1 a, ASIC1 b, ASIC2a, ASIC2b, ASIC3,
and
ASIC4, among others. In some examples, the inhibitors may reduce the channel
activity of one or more members, such as the ability of the members to flux
ions
(e.g., sodium, calcium, and/or potassium ions, among others) through cell
membranes (into and/or out of cells). The substances may be compounds (small
molecules of less than about 10 kDa, peptides, nucleic acids, lipids, etc.),
complexes
of two or more compounds, and/or mixtures, among others. Furthermore, the
substances may inhibit ASIC family members by any suitable mechanism including
competitive, noncompetitive, uncompetitive, and/or mixed inhibition, among
others.
The inhibitor may be an ASIC1 a inhibitor that inhibits acid sensing ion
channel
1 a(ASIC1 a). ASIC1 a, as used herein, refers to an ASIC1 a protein or channel
from
any species. For example, an exemplary human ASIC1 a protein/channel is
described in Waldmann, R., et al. 1997, Nature 386, pp. 173-177, which is
incorporated herein by reference.
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
7
The expression "ASIC1 a inhibitor" may refer to a product which, within the
scope of sound pharmacological judgment, is potentially or actually
pharmaceutically
useful as an inhibitor of ASIC1a, and includes reference to substances which
comprise a pharmaceutically active species and are described, promoted, or
authorized as an ASIC1 a inhibitor.
An ASIC1 a inhibitor may be selective within the ASIC family. Selective
inhibition of ASIC1 a, as used herein, is inhibition that is substantially
stronger on
ASIC1 a than on another ASIC family member(s) when compared (for example, in
cultured cells) after exposure of each to the same (sub-maximal)
concentration(s) of
an inhibitor. The inhibitor may inhibit ASIC1a selectively relative to at
least one other
ASIC family member (ASIC1 b, ASIC2a, ASIC2b, ASIC3, ASIC 4, etc.) and/or
selectively relative to every other ASIC family member. The strength of
inhibition for
a selective inhibitor may be described by an inhibitor concentration at which
inhibition occurs (e.g., an IC50 (inhibitor concentration that produces 50% of
maximal
inhibition) or a K; value (inhibition constant or dissociation constant))
relative to
different ASIC family members. An ASIC1 a-selective inhibitor may inhibit
ASIC1 a
activity at a concentration that is at least about two-, four-, or ten-fold
lower (one-half,
one-fourth, or one-tenth the concentration or lower) than for inhibition of at
least one
other or of every other ASIC family member. Accordingly, an ASIC1 a-selective
inhibitor may have an IC50 and/or K; for ASIC1 a inhibition that is at least
about two-,
four-, or ten-fold lower (one-half, one-fourth, or one-tenth or less) than for
inhibition
of at least one other ASIC family member and/or for inhibition of every other
ASIC
family member.
An ASIC1 a-selective inhibitor, in addition to being selective, also may be
specific for ASIC1 a. ASIC1 a-specific inhibition, as used herein, is
inhibition that is
substantially exclusive to ASIC1 a relative to every other ASIC family member.
An
ASIC1 a-specific inhibitor may inhibit ASIC1 a at an inhibitor concentration
that is at
least about twenty-fold lower (5% of the concentration or less) than for
inhibition of
every other ASIC family member. Accordingly, an ASIC1 a-specific inhibitor may
have an IC50 and/or K; for ASIC1 a relative to every other member of the ASIC
family
that is at least about twenty-fold lower (five percent or less), such that,
for example,
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
8
inhibition of other ASIC family members is at least substantially (or
completely)
undetectable.
Any suitable ASIC inhibitor or combination of inhibitors may be used. For
example, a subject may be treated with an ASIC1 a-selective inhibitor and a
nonselective ASIC inhibitor, or with an ASIC1 a-selective inhibitor and an
inhibitor to
a non-ASIC channel protein, such as a non-ASIC calcium channel. In some
examples, a subject may be treated with an ASIC1 a-selective inhibitor and an
inhibitor of NMDA receptors, such as a glutamate antagonist.
The inhibitor may be or include a peptide. The peptide may have any suitable
number of amino acid subunits, generally at least about ten and less than
about one-
thousand subunits. In some examples, the peptide may have a cystine knot
motif. A
cystine knot, as used herein, generally comprises an arrangement of six or
more
cysteines. A peptide with these cysteines may create a "knot" including (1) a
ring
formed by two disulfide bonds and their connecting backbone segments, and (2)
a
third disulfide bond that threads through the ring. In some examples, the
peptide may
be a conotoxin from an arachnid and/or cone snail species. For example, the
peptide
may be PcTxl (psalmotoxin 1), a toxin from a tarantula (Psalmopoeus cambridgei
(PO -
In some examples, the peptide may be structurally related to PcTxl, such that
the peptide and PcTxl differ by at least one deletion, insertion, and/or
substitution of
one or more amino acids. For example, the peptide may have at least about 25%
or
at least about 50% sequence identity, and/or at least about 25% or at least
about
50% sequence similarity with PcTxl (see below). Further aspects of peptides
that
may be suitable as inhibitors are described below in Example 3.
Methods of alignment of amino acid sequences for comparison and
generation of identity and similarity scores are well known in the art.
Exemplary
alignment methods that may be suitable include (Best Fit) of Smith and
Waterman, a
homology alignment algorithm (GAP) of Needleman and Wunsch, a similarity
method (Tfasta and Fasta) of Pearson and Lipman, and/or the like. Computer
algorithms of these and other approaches that may be suitable include, but are
not
limited to: CLUSTAL, GAP, BESTFIT, BLASTP, FASTA, and TFASTA.
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
9
As used herein, "sequence identity" or "identity" in the context of two
peptides
relates to the percentage of residues in the corresponding peptide sequences
that
are the same when aligned for maximum correspondence. In some examples,
peptide residue positions that are not identical may differ by conservative
amino acid
substitutions, where amino acid residues are substituted for other amino acid
residues with similar chemical properties (e.g. charge or hydrophobicity) and
therefore are expected to produce a smaller (or no) effect on the functional
properties of the molecule. Where sequences differ in conservative
substitutions, the
percent sequence identity may be adjusted upwards, to give a "similarity" of
the
sequences, which corrects for the conservative nature of the substitutions.
For
example, each conservative substitution may be scored as a partial rather than
a full
mismatch, thereby correcting the percentage sequence identity to provide a
similarity
score. The scoring of conservative substitutions to obtain similarity scores
is well
known in the art and may be calculated by any suitable approach, for. example,
according to the algorithm of Meyers and Miller, Computer Applic. Biol Sci.,
4: 11-17
(1988), e.g., as implemented in the program PC/GENE (Intelligenetics, Mountain
View, Calif., USA).
IV. Administration of Inhibitors
Administration (or administering), as used herein, includes any route of
subject exposure to an inhibitor, under any suitable conditions, and at any
suitable
time(s). Administration may be self-administration or administration by
another, such
as a health-care practitioner (e.g., a doctor, a nurse, etc.). Administration
may be by
injection (e.g., intravenous, intramuscular, subcutaneous, intracerebral,
epidural,
and/or intrathecal, among others), ingestion (e.g., using a capsule, lozenge,
a fluid
composition, etc.), inhalation (e.g., an aerosol (less than about 10 microns
average
droplet diameter) inhaled nasally and/or orally), absorption through the skin
(e.g.,
with a skin patch) and/or mucosally (e.g., through oral, nasal, and/or
pulmonary
mucosa, among others), and/or the like. Mucosal administration may be
achieved,
for example, using a spray (such as a nasal spray), an aerosol that is
inhaled),
and/or the like. A spray may be a surface spray (droplets on average greater
than
about 50 microns in diameter) and/or a space spray (droplets on average about
10-
50 microns in diameter). In some examples, ischemia may produce an alteration
of
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
the blood-brain barrier of an ischemic subject, thus increasing the efficiency
with
which an inhibitor that is introduced (e.g., by injection and/or absorption)
into the
bloodstream of a subject can reach the brain. Administration may be performed
once
or a plurality of times, and at any suitable time relative to ischemia
diagnosis, to
5 provide treatment. Accordingly, administration may be performed before
ischemia
has been detected (e.g., prophylactically,) after a minor ischemic episode,
during
chronic ischemia, after a full stroke, and/or the like.
A therapeutically effective amount of an inhibitor may be administered. A
therapeutically effective amount of an inhibitor, as used herein, is any
amount of the
10 inhibitor that, when administered to subjects, reduces, in a significant
number of the
subjects, the degree, incidence, and/or extent of ischemia-induced injury in
the
subjects. Accordingly, a therapeutically effective amount may be determined,
for
example, in clinical studies in which various amounts of the inhibitor are
administered to test subjects (and, generally, compared to a control group of
subjects).
The inhibitor may be administered in any suitable form and in any suitable
composition to subjects. In some examples, the inhibitor may be configured as
a
pharmaceutically acceptable salt. The composition may be formulated to
include, for
example, a fluid carrier/solvent (a vehicle), a preservative, one or more
excipients, a
coloring agent, a flavoring agent, a salt(s), an anti-foaming agent, and/or
the like.
The inhibitor may be present at a concentration in the vehicle that provides a
therapeutically effective amount of the inhibitor for treatment of ischemia
when
administered to an ischemic subject.
V. Identification of Drugs
Additional ASIC inhibitors may be identified for use as drugs to treat
ischemia.
Identification may include (A) obtaining one or more ASIC inhibitors, and (B)
testing
the ASIC inhibitors on ischemic subjects.
A. Obtaininq ASIC Inhibitors
One or more ASIC inhibitors, particularly ASIC1 a inhibitors as described
above, may be obtained. The inhibitors may be obtained by any suitable
approach,
such by screening a set of candidate inhibitors (e.g., a library of two or
more
compounds) and/or by rationale design, among others.
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
11
Screening may involve any suitable assay system that measures interaction
between ASIC proteins and the set of candidate inhibitors. Exemplary assay
systems
may include assays performed biochemically (e.g., binding assays), with cells
grown
in culture ("cultured cells"), and/or with organisms, among others.
A cell-based assay system may measure an effect, if any, of each candidate
inhibitor on ion flux in the cells, generally acid-sensitive ion flux. In some
examples,
the ion flux may be a flux of calcium and/or sodium, among others. The assay
system may use cells expressing an ASIC family member, such as ASIC1 a, or two
or more distinct sets of cells expressing two or more distinct ASIC family
members,
such as ASIC1a and another ASIC family member(s), to determine the selectivity
of
each inhibitor for these family members. The cells may express each ASIC
family
member endogenously or through introduction of foreign nucleic acid. In some
examples, the assay system may measure ion flux electrophysiologically (such
as by
patch clamp), using an ion-sensitive or membrane potential-sensitive dye
(e.g., a
calcium sensitive dye such as Fura-2), or via a gene-based reporter system
that is
sensitive to changes in membrane potential and/or intracellular ion (e.g.,
calcium)
concentrations, among others. The assay system may be used to test candidate
inhibitors for selective and/or specific inhibition of ASIC family members,
particularly
ASIC1 a.
B. Testing ASIC Inhibitors on Subjects
One or more ASIC inhibitors may be administered to an ischemic subject(s) to
test the efficacy of the inhibitors for treatment of ischemia. The ischemic
subjects
may be people or animals. In some examples, the ischemic subjects may provide
an
animal model system of ischemia and/or stroke. Exemplary animal model systems
include rodents (mice and/or rats, among others) with ischemia induced
experimentally. The ischemia may be induced mechanically (e.g., surgically)
and/or
by administration of a drug, among others. In some examples, the ischemia may
be
induced by occlusion of a blood vessel, such as by constriction of a mid-
cerebral
artery.
VI. Examples
The following examples describes selected aspects and embodiments of the
present teachings, particularly data describing in vitro and in vivo effects
of ASIC
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
12
inhibition, and exemplary cystine knot peptides for use as inhibitors. These
examples
are intended for the purposes of illustration and should not be construed to
limit the
scope of the present teachings.
Example 1: Neuroprotection in Ischemia Blocking Calcium-Permeable
Acid-Sensing Ion Channels
This example describes experiments showing a role of ASIC1 a in mediating
ischemic injury and the ability ASIC1 a inhibitors to reduce ischemic injury;
see
Figures 2-10.
A. Overview
Ca2+ toxicity may play a central role in ischemic brain injury. The mechanism
by which toxic Ca2+ loading of cells occurs in the ischemic brain has become
less
clear as multiple human trials of glutamate antagonists have failed to show
effective
neuroprotection in stroke. Acidosis may be a common feature of ischemia and
may
play a critical role in brain injury; however, the mechanism(s) remains ill
defined.
Here, we show that acidosis may activate Ca2+-permeable acid-sensing ion
channels
(ASICs), which may induce glutamate receptor-independent, Ca2+-dependent,
neuronal injury inhibited by ASIC blockers. Cells lacking endogenous ASICs may
be
resistant to acid injury, while transfection of Ca2+-permeable ASIC1a may
establish
sensitivity. In focal ischemia, intracerebroventricular injection of ASIC1a
blockers or
knockout of the ASIC1a gene may protect the brain from ischemic injury and may
do
so more potently than glutarnate antagonism. Thus, acidosis may injure the
brain via
membrane receptor-based rnechanisms with resultant toxicity of [Ca2+];
(intracellular
calcium), disclosing new potential therapeutic targets for stroke.
B. Introduction
Intracellular Ca2+ overload may be important for neuronal injury associated
with neuropathological syndromes, including brain ischemia (Choi 1995 and Choi
1988a). Excessive Ca2+ in the cell may activate a cascade of cytotoxic events
leading to activation of enzymes that break down proteins, lipids, and nucleic
acids.
NMDA receptors, which rnay be the most important excitatory neurotransmitter
receptors in the central nervous system (McLennan 1983 and Dingledine et al.
1999), have long been considered the main target responsible for Ca2+ overload
in
the ischemic brain (Simon et al. 1984; Rothman and Olney 1986; Choi 1988b and
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
13
Meldrum 1995). However, recent clinical efforts to prevent brain injury
through the
therapeutic use of NMDA receptor antagonists have been disappointing (Lee et
al.
1999 and Wahlgren and Ahmed 2004). Although multiple factors, including
difficulty
in early initiation of treatment, may have contributed to trial failures,
glutamate
receptor-independent Ca2+ toxicity also or alternatively may be responsible
for
ischemic brain injury.
The normal brain may require complete oxidation of glucose to fulfill its
energy
requirements. During ischemia, oxygen depletion rmay force the brain to switch
to
anaerobic glycolysis. Accumulation of lactic acid as a byproduct of glycolysis
and
protons produced by ATP hydrolysis may cause pH to fall in the ischemic brain
(Rehncrona 1985 and Siesjo et al. 1996). Consequently, tissue pH typically
falls to
6.5-6.0 during ischemia under normoglycemic conditions and may fall below 6.0
during severe ischemia or under hyperglycemic conditions (Nedergaard et al.
1991;
Rehncrona 1985 and Siesjo et al. 1996). Nearly all in vivo studies indicate
that
acidosis aggravates ischemic brain injury (Tombaugh and Sapolsky 1993 and
Siesjo
et al. 1996). However, the mechanisms of this process remain unclear, although
a
host of possibilities has been suggested (Siesjo et al. 1996; McDonald et al.
1998;
Swanson et al. 1995 and Ying et al. 1999).
Acid-sensing ion channels (ASICs), a newly described class of ligand-gated
channels (Waidmann et al. 1997a and Krishtal 2003), have been shown to be
expressed throughout neurons of mammalian central and peripheral nervous
systems (Waidmann et al. 1997a; Waldmann et al. 1999; Waldmann and Lazdunski
1998; Krishtal 2003; Alvarez de Ia Rosa et al. 20D2 and Alvarez de Ia Rosa et
al.
2003). These channels are members of the degenerin/epithelial sodium channel
(Deg/ENaC) superfamily (Benos and Stanton 1999; Bianchi and Driscoll 2002 and
Krishtal 2003). Pertinent to ischemia, ASICs also may flux Ca2+ (Waldmann et
al.
1997a; Chu et al. 2002 and Yermolaieva et al. 2004).
To date, six ASIC subunits have been cloned. Four of these subunits may
form functional homomultimeric channels that are activated by acidic pH to
conduct a
sodium-selective, amiloride-sensitive, cation current. The pH of half-maximal
activation (pHo.5) of these channels differs: ASIC1 a, pH0.5 = 6.2 (Waldmann
et al.,
1997a); ASIC1p (also termed ASIC1b), a splice variant of ASIC1a with a unique
N-
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
14
terminal, pHo,5 = 5.9 (Chen et al., 1998); ASIC2a, pH0.5 = 4.4 (Waldmann et
al.,
1999); and ASIC3, pH0.5 = 6.5 (Waldmann et al., 1997b). Neither ASIC2b nor
ASIC4
can form functional homomeric channel (Akopian et al. 2000; Grunder et al.
2000
and Lingueglia et al. 1997), but ASIC2b has been shown to associate with other
subunits and modulate their activity (Lingueglia et al., 1997). In addition to
Na+
permeability, homomeric ASIC1 a may flux Ca2+ (Waldmann et al. 1997a; Chu et
al.
2002 and Yermolaieva et al. 2004). Although the exact subunit composition of
ASICs
in native neurons has not been determined, both ASIC1a and ASIC2a subunits
have
been shown to be abundant in the brain (Price et al. 1996; Bassilana et al.
1997;
Wemmie et al. 2002 and Alvarez de Ia Rosa et al. 2003).
Detailed functions of ASICs in both peripheral and central nervous systems
remain to be determined. In peripheral sensory neurons, ASICs have been
implicated in mechanosensation (Price et al. 2000 and Price et al. 2001) and
perception of pain during tissue acidosis (Bevan and Yeats 1991; Krishtal and
Pidoplichko 1981; Ugawa et al. 2002; Sluka et al. 2003 and Chen et al. 2002),
particularly in ischemic myocardium where ASICs likely transduce anginal pain
(Benson et al., 1999). The presence of ASICs in the brain, which lacks
nociceptors,
suggests that these channels may have functions beyond nociception. Indeed,
recent studies have indicated that ASIC1 a may be involved in synaptic
plasticity,
learning/memory, and fear conditioning (Wemmie et al. 2002 and Wemmie et al.
2003). Here, using a combination of patch-clamp recording, Ca2+ imaging,
receptor
subunit transfection, in vitro cell toxicity assays, and in vivo ischemia
models
combined with gene knockout, we demonstrate activation of Ca2+-permeable ASIC1
a
as largely responsible for glutamate-independent, acidosis-mediated, and
ischemic
brain injury.
C. Results
1. Acidosis Activates ASICs in Mouse Cortical Neurons
Figures 3 and 4 shows exemplary data related to the electrophysiology and
pharmacology of ASICs in cultured mouse cortical neurons. Figures 3A and 3B
are
graphs illustrating the pH dependence of ASIC currents activated by a pH drop
from
7.4 to the pH values indicated. Dose-response curves were fit to the Hill
equation
with an average pH0.5 of 6.18 0.06 (n = 10). Figures 3C and 3D are graphs
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
illustrating the current-voltage relationship of ASICs (n = 5). The amplitudes
of ASIC
current at various voltages were normalized to that recorded at -60 mV.
Figures 4A
and 4B are graphs illustrating a dose-dependent blockade of ASIC currents by
amiloride. IC50 = 16.4 4.1 pM, N = 8. Figures 4C and 4D are graphs
illustrating a
5 blockade of ASIC currents by PcTX venom. **p < 0.01.
We first recorded ASIC currents in cultured mouse cortical neurons, a
preparation commonly used for cell toxicity studies (Koh and Choi 1987 and
Sattler
et al. 1999); see Figure 3. At a holding potential of -60 mV, a rapid
reduction of
extracellular pH (pHe) to below 7.0 evoked large transient inward currents
with a
10 small steady-state component in the majority of neurons (Figure 3A). The
amplitude
of inward current increased in a sigmoidal fashion as pHe decreased, yielding
a pH0,5
of 6.18 0.06 (n = 10, Figure 3B). A linear I-V relationship and a reversal
close to
the Na+ equilibrium potential were obtained (n = 6, Figures 3C and 3D). These
data
demonstrate that lowering pHe may activate typical ASICs in mouse cortical
neurons.
15 We then tested the effect of amiloride, a nonspecific blocker of ASICs
(Waidmann et al., 1997a), on the acid-activated currents; see Figure 4.
Similar to
previous studies, mainly in sensory neurons (Waldmann et al. 1997a; Benson et
al.
1999; Chen et al. 1998 and Varming 1999), amiloride dose-dependently blocked
ASIC currents in cortical neurons with an IC50 of 16.4 4.1 pM (n = 8,
Figures 4A
and 4B). Psalmotoxin 1 (or PcTX1) from venom of the tarantula Psalmopoeus
cambridgei (PcTX venom) may be a specific ASIC1 a blocker (Escoubas et al.,
2000). Our studies show that, at a protein concentration of 25 ng/mL, PcTX
venom
itself may block the current mediated by homomeric ASIC1 a expressed in COS-7
cells by -70% (n = 4, see Supplemental Figure S1 at
http://www.cell.com/cgi/content/full/118/6/687/DC1, which is incorporated
herein by
reference). However, it does not affect currents mediated by heteromeric ASIC1
a/2a,
homomeric ASIC2a, or ASIC3 channels at 500 ng/mL (n = 4-6). In addition, at
500
ng/mL, PcTX venom does not affect the currents through known voltage- and
ligand-
gated channels, further indicating its specificity for homomeric AS IC 1 a(n =
4-5,
Supplemental Figure S2, and Supplemental Data (at the website cited above),
which
are incorporated herein by reference).
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
16
We then tested the effect of PcTX venom on acid-activated current in cortical
neurons. At 100 ng/mL, PcTX venom reversibly blocked the peak amplitude of
ASIC
current by 47% 7% (n = 15, Figures 4C and 4D), indicating significant
contributions
of homomeric ASIC1 a to total acid-activated currents. Increasing PcTX
concentration
did not induce further reduction in the amplitude of ASIC current in the
majority of
cortical neurons (n = 8, data not shown), indicating coexistence of PcTX-
insensitive
ASICs (e.g., heteromeric ASIC1 a/2a) in these neurons.
2. ASIC Response Is Potentiated by Modeled Ischemia
Figure 5 shows exemplary data indicating that modeled ischemia may
enhance activity of ASICs. Figure 5A is a series of exemplary traces showing
an
increase in amplitude and a decrease in desensitization of ASIC currents
following 1
hr OGD. Figure 5B is a graph of summary data illustrating an increase of ASIC
current amplitude in OGD neurons. N = 40 and 44, *p < 0.05. Figure 5C is a
series of
exemplary traces and summary data showing decreased ASIC current
desensitization in OGD neurons. N = 6, **p < 0.01. Figure 5D is a pair of
exemplary
traces showing lack of acid-activated current at pH 6.0 in ASIC1-/- neurons,
in
control condition, and following 1 hr OGD (n = 12 and 13).
Since acidosis may be a central feature of brain ischemia, we determined
whether ASICs may be activated in ischemic conditions and whether ischemia may
modify the properties of these channels; see Figure 5. We recorded ASIC
currents in
neurons following 1 hr oxygen glucose deprivation (OGD), a common model of in
vitro ischemia (Goldberg and Choi, 1993). One set of cultures was washed three
times with glucose-free extracellular fluid (ECF) and subjected to OGD, while
control
cultures were subjected to washes with glucose containing ECF and incubation
in a
conventional cell culture incubator. OGD was terminated after 1 hr by
replacing
glucose-free ECF with Neurobasal medium and incubating cultures in the
conventional incubator. ASIC current was then recorded 1 hr following the OGD
when there was no morphological alteration of neurons. OGD treatment induced a
moderate increase of the amplitude of ASIC currents (1520 138 pA in control
group, N = 44; 1886 185 pA in neurons following 1 hr OGD, N = 40, p < 0.05,
Figures 5A and 5B). More importantly, OGD induced a dramatic decrease in ASIC
desensitization as demonstrated by an increase in time constant of the current
decay
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
17
(814.7 58.9 ms in control neurons, N = 6; 1928.9 315.7 ms in neurons
following
OGD, N= 6, p < 0.01, Figures 5A and 5C). In cortical neurons cultured from
ASIC1-/- mice, reduction of pH from 7.4 to 6.0 did not activate any inward
current (n
= 52), similar to a previous study in hippocampal neurons (Wemmie et al.,
2002). In
these neurons, 1 hr OGD did not activate or potentiate acid-induced responses
(Figure 5D, n = 12 and 13).
3. Acidosis Induces Glutamate-Independent Ca2+ Entry via ASIC1a
Figures 6 and 7 show exemplary data suggesting that ASICs in Cortical
Neurons may be Ca2+ permeable, and that Ca2+ permeability may be ASIC1 a
dependent. Figure 6A shows exemplary traces obtained with Na+-free ECF
containing 10 mM Ca2+ as the only charge carrier. Inward currents were
recorded at
pH 6Ø The average reversal potential is -17 mV after correction of liquid
junction
potential (n = 5). Figure 6B shows representative traces and summary data
illustrating blockade of Ca2+-mediated current by amiloride and PcTX venom.
The
peak amplitude of Ca2+-mediated current decreased to 26% 2% of control value
by
100 pM amiloride (n = 6, p < 0.01) and to 22% 0.9% by 100 ng/mL PcTX venom
(n
= 5, p < 0.01). Figure 7A shows exemplary 340/380 nm ratios as a function of
pH,
illustrating an increase of [Ca2+]; by pH drop to 6Ø Neurons were bathed in
normal
ECF containing 1.3 mM CaCI2 with blockers for voltage-gated Ca2+ channels (5
pM
nimodipine and 1 pM w-conotoxin MVIIC) and glutamate receptors (10 pM MK801
and 20 pM CNQX). The inset of Figure 7A shows exemplary inhibition of acid-
induced increase of [Ca2+]; by 100 pM amiloride. Figure 7B shows exemplary
summary data illustrating inhibition of acid-induced increase of [Ca2+]; by
amiloride
and PcTX venom. N = 6-8, **p < 0.01 compared with pH 6.0 group. Figure 7C
shows exemplary 340/380 nm ratios as a function of pH and NMDA
presence/absence, demonstrating a lack of acid-induced increase of [Ca2+]; in
ASIC1-/- neurons; neurons had a normal response to NMDA (n = 8). Figure 7D
shows exemplary traces illustrating a lack of acid-activated current at pH 6.0
in
ASIC1-/- neurons.
Using a standard ion-substitution protocol (Jia et al., 1996) and the Fura-2
fluorescent Ca2+-imaging technique (Chu et al., 2002), we determined whether
ASICs in cortical neurons are Ca2+ permeable; see Figures 6 and 7. With bath
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
18
solutions containing 10 mM Ca2+ (Na+ and K+-free) as the only charge carrier
and at
a holding potential of -60 mV, we recorded inward currents larger than 50 pA
in 15
out of 18 neurons, indicating significant Ca2+ permeability of ASICs in the
majority of
cortical neurons (Figure 6A). Consistent with activation of homomeric ASIC1 a
channels, currents carried by 10 mM Ca2+ were largely blocked by both the
nonspecific ASIC blocker amiloride and the ASIC1 a-specific blocker PcTX venom
(Figure 6B). The peak amplitude of Ca2+-mediated current was decreased to 26%
2% of control by 100 pM amiloride (n = 6, p < 0.01) and to 22% 0.9% by 100
ng/mL
PcTX venom (n = 5, p < 0.01). Ca2+ imaging, in the presence of blockers of
other
major Ca2+ entry pathways (MK801 10 pM and CNQX 20 pM for glutamate
receptors; nimodipine 5 pM and w-conotoxin MVIIC 1 pM for voltage-gated Ca2+
channels), demonstrated that 18 out of 20 neurons responded to a pH drop with
detectable increases in the concentration of intracellular Ca2+ ([Ca2+];)
(Figure 7A). In
general, [Ca2+]; remains elevated during prolonged perfusion of low pH
solutions. In
some cells, the [Ca2+]; increase lasted even longer than the duration of acid
perfusion
(Figure 7A). Long-lasting Ca2+ responses suggest that ASIC response in intact
neurons may be less desensitized than in whole-cell recordings or that Ca2+
entry
through ASICs may induce subsequent Ca2+ release from intracellular stores.
Preincubation of neurons with 1 pM thapsigargin partially inhibited the
sustained
component of Ca2+ increase, suggesting that Ca2+ release from intracellular
stores
may also contribute to acid-induced intracellular Ca2} accumulation (n = 6,
data not
shown). Similar to the current carried by Ca2+ ions (Figure 6B), both peak and
sustained increases in [Ca2+]; were largely inhibited by amiloride and PcTX
venom
(Figures 7A and 7B, n = 6-8), consistent with involvement of homomeric ASIC1 a
in
acid-induced [Ca2+]; increase. Knockout of the ASIC1 gene eliminated the acid-
induced [Ca2+]; increase in all neurons without affecting NMDA receptor-
mediated
Ca2+ response (Figure 7C, n = 8). Patch-clamp recordings demonstrated lack of
acid-activated currents at pH 6.0 in 52 out of 52 of the ASIC1-1- neurons,
consistent
with absence of ASIC1 a subunits. Lowering pH to 5.0 or 4.0, however,
activated
detectable current in 24 out of 52 ASIC1-/- neurons, indicating the presence
of
ASIC2a subunits in these neurons (Figure 7D). Further electrophysiological
studies
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
19
demonstrated that ASIC1-l- neurons have normal responses for various voltage-
gated channels and NMDA, GABA receptor-gated channels (data not shown).
4. ASIC Blockade Protects against Acidosis-Induced,
Glutamate-Independent Neuronal InLury
Figure 8 shows exemplary data suggesting that acid incubation may induce
glutamate receptor-independent neuronal injury protected by ASIC blockade.
Figures
8A and 8B show graphs presenting exemplary data for time-dependent LDH release
induced by 1 hr (Figure 8A) or 24 hr incubation (Figure 8B) of cortical
neurons in pH
7.4 (solid bars) or 6.0 ECF (open bars). N = 20-25 wells, *p < 0.05, and **p <
0.01,
compared to pH 7.4 group at the same time points. (Acid-induced neuronal
injury
with fluorescein diacetate (FDA) also was analyzed by staining of cell bodies
of alive
neurons and propidium iodide (PI) staining of nuclei of dead neurons.) Figure
8C
shows a graph illustrating inhibition of acid-induced LDH release by 100 pM
amiloride or 100 ng/mL PcTX venom (n = 20-27, *p < 0.05, and **p < 0.01).
MK801,
CNQX, and nimodipine were present in ECF for all experiments (Figures 8A-C).
Acid-induced injury was studied on neurons grown on 24-well plates
incubated in either pH 7.4 or 6.0 ECF containing MK801, CNQX, and nimodipine;
see Figure 8. Cell injury was assayed by the measurement of lactate
dehydrogenase
(LDH) release (Koh and Choi, 1987) at various time points (Figures 8A and 8B)
and
by fluorescent staining of alive/dead cells. Compared to neurons treated at pH
7.4, 1
hr acid incubation (pH 6.0) induced a time-dependent increase in LDH release
(Figure 8A). After 24 hr, 45.7% 5.4% of maximal LDH release was induced (n =
25
wells). Continuous treatment at pH 6.0 induced greater cell injury (Figure 8B,
n = 20).
Consistent with the LDH assay, alive/dead staining with fluorescein diacetate
(FDA,
blue) and propidium iodide (PI, red) showed similar increases in cell death by
1 hr
acid treatment (see Supplemental Figure S3 (on the web site cited above),
which is
incorporated herein by reference). One hour incubation with pH 6.5 ECF also
induced significant but less LDH release than with pH 6.0 ECF (n = 8 wells).
To determine whether activation of ASICs is involved in acid-induced
glutamate receptor-independent neuronal injury, we tested the effect of
amiloride
and PcTX venom on acid-induced LDH release. Addition of either 100 pM
amiloride
or 100 ng/mL PcTX venom 10 min before and during the 1 hr acid incubation
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
significantly reduced LDH release (Figure 8C). At 24 hr, LDH release was
decreased
from 45.3% 3.8% to 31.1 % 2.5% by amiloride and to 27.9% 2.6% by PcTX
venom (n = 20-27, p < 0.01). Addition of amiloride or PcTX venom in pH 7.4 ECF
for
1 hr did not affect baseline LDH release, although prolonged incubation (e.g.,
5 hr)
5 with amiloride alone increased LDH release (n = 8).
5. Activation of Homomeric AS/C1a May be Responsible for
Acidosis-Induced Injury
Figure 9 is a series of graphs presenting exemplary data indicating that
ASIC1 a may be involved in acid-induced injury in vitro. Figure 9A shows
exemplary
10 data illustrating inhibition of acid-induced LDH release by reducing
[Ca2+]e (n = 11-
12, **p < 0.01 compared with pH 6.0, 1.3 Ca2+). Figure 9B shows exemplary data
illustrating acid incubation induced increase of LDH release in ASIC1a-
transfected
but not nontransfected COS-7 cells (n = 8-20). Amiloride (100 pM) inhibited
acid-
induced LDH release in ASIC1 a-transfected cells. *p < 0.05 for 7.4 versus 6.0
and
15 6.0 versus 6.0 + amiloride. Figure 9C shows exemplary data illustrating a
lack of
acid-induced injury and protection by amiloride and PcTX venom in ASIC1-/-
neurons (n = 8 in each group, p> 0.05). Figure 9D shows exemplary data
illustrating
acid-induced increase of LDH release in cultured cortical neurons under OGD (n
=
5). LDH release induced by combined 1 hr OGD/acidosis was not inhibited by
trolox
20 and L-NAME (n = 8-11). OGD did not potentiate acid-induced LDH release in
ASIC1-/- neurons. **p < 0.01 for pH 7.4 versus pH 6.0 and *p < 0.05 for pH 6.0
versus 6.0 + PcTX venom. MK801, CNQX, and nimodipine were present in ECF for
all experiments (Figure 9A-D).
To determine whether Ca2+ entry plays a role in acid-induced injury, we
treated neurons with pH 6.0 ECF in the presence of normal or reduced [Ca2+]ei
see
Figure 9. Reducing Ca2+ from 1.3 to 0.2 mM inhibited acid-induced LDH release
(from 40.0% 4.1 % to 21.9% 2.5%), as did ASIC1 a blockade with PcTX venom
(n
= 11-12, p < 0.01; Figure 9A). Ca2+-free solution was not tested, as a
complete
removal of [Ca2+]e may activate large inward currents through a Ca2+-sensing
cation
channel, which may otherwise complicate data interpretation (Xiong et al.,
1997).
Inhibition of acid injury by both amiloride and PcTX, nonspecific and specific
ASIC1 a
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
21
blockers, and by reducing [Ca2+]e suggests that activation of Ca2+-permeable
ASIC1 a
may be involved in acid-induced neuronal injury.
To provide additional evidence that activation of ASIC1 a is involved in acid
injury, we studied acid injury of nontransfected and ASIC1 a transfected COS-7
cells,
a cell line commonly used for expression of ASICs due to its lack of
endogenous
channels (Chen et al. 1998; lmmke and McCleskey 2001 and Escoubas et al.
2000).
Following confluence (36-48 hr after plating), cells were treated with either
pH 7.4 or
6.0 ECF for 1 hr. LDH release was measured 24 hr after acid incubation.
Treatment
of nontransfected COS-7 cells with pH 6.0 ECF did not induce increased LDH
release when compared with pH 7.4-treated cells (10.3% 0.8% for pH 7.4, and
9.4% 0.7% for pH 6.0, N = 19 and 20 wells; p > 0.05, Figure 9B). However, in
COS-7 cells stably transfected with ASIC1 a, 1 hr incubation at pH 6.0
significantly
increased LDH release from 15.5% 2.4% to 24.0% 2.9% (n = 8 wells, p <
0.05).
Addition of amiloride (100 gM) inhibited acid-induced LDH release in these
cells
(Figure 9B).
We also studied acid injury of CHO cells transiently transfected with cDNAs
encoding GFP alone or GFP plus ASIC1a. After the transfection (24-36 hr),
cells
were incubated with acidic solution (pH 6.0) for 1 hr, and cell injury was
assayed 24
hr following the acid incubation. As shown in Supplemental Figure S4 (at the
website
cited above), which is incorporated herein by reference, 1 hr acid incubation
largely
reduced surviving GFP-positive cells in GFP/ASIC1a group but not in the group
transfected with GFP alone (n = 3 dishes in each group).
To further demonstrate an involvement of ASIC1 a in acidosis-induced
neuronal injury, we performed cell toxicity experiments on cortical neurons
cultured
from ASIC+/+ and ASIC1-l- mice (Wemmie et al., 2002). Again, 1 hr acid
incubation of
ASIC+'+ neurons at 6.0 induced substantial LDH release that was reduced by
amiloride and PcTX venom (n = 8-12). One hour acid treatment of ASIC1-l-
neurons, however, did not induce significant increase in LDH release at 24 hr
(13.8%
0.9% for pH 7.4 and 14.2% 1.3% for pH 6.0, N = 8, p > 0.05), indicating
resistance of these neurons to acid injury (Figure 9C). In addition, knockout
of the
ASIC1 gene also eliminated the effect of amiloride and PcTX venom on acid-
induced
LDH release (Figure 9C, n = 8 each), further suggesting that the inhibition of
acid-
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
22
induced injury of cortical neurons by amiloride and PcTX venom (Figure 8C) was
due
to blockade of ASIC1 subunits. In contrast to acid incubation, 1 hr treatment
of
ASIC1-/- neurons with 1 mM NMDA + 10 pM glycine (in Mg2+-free [pH 7.4] ECF)
induced 84.8% 1.4% of maximal LDH release at 24 hr (n = 4, Figure 9C),
indicating
normal response to other cell injury processes.
6_ Modeled Ischemia Enhances Acidosis-Induced
Glutamate-Independent Neuronal Injury via AS/Cs
As the magnitude of ASIC currents may be potentiated by cellular and
neurochemical components of brain ischemia-cell swelling, arachidonic acid,
and
lactate (Allen and Attwell 2002 and lmmke and McCieskey 2001)-and, more
importantly, the desensitization of ASIC currents may be reduced dramatically
by
modeled ischemia (see Figures 5A and 5C), we expected that activation of ASICs
in
ischemic conditions should produce greater neuronal injury. To test this
hypothesis,
we subjected neurons to 1 hr acid treatment under oxygen and glucose
deprivation
(OGD). MK801, CNQX, and nimodipine were added to all solutions to inhibit
voltage-
gated Ca2+ channels and glutamate receptor-mediated cell injury associated
with
OGD (Kaku et al., 1991). One hour incubation with pH 7.4 ECF under OGD
conditions induced only 27.1 % 3.5% of maximal LDH release at 24 hr (n = 5,
Figure 9D). This finding is in agreement with a previous report that 1 hr OGD
does
not induce substantial cell injury with the blockade of glutamate receptors
and
voltage-gated Ca2+ channels (Aarts et al., 2003). However, 1 hr OGD, combined
with
acidosis (pH 6.0), induced 73.9% 4.3% of maximal LDH release (n = 5, Figure
9D,
p < 0.01 ), significantly larger than acid-induced LDH release in the absence
of OGD
(see Figure 8A, p < 0.05). Addition of the ASIC1 a blocker PcTX venom (100
ng/mL)
significantly reduced acid/OGD-induced LDH release to 44.3% 5.3% (n = 5, p <
0.05, Figure 9D).
We also performed the same experiment with cultured neurons from the
ASIC1-/- mice. Unlike in ASIC1 containing neurons, however, 1 hr treatment
with
combined OGD and acid only slightly increased LDH release in ASIC1-/- neurons
(from 26.1 % 2.7% to 30.4% 3.5%, N = 10-12, Figure 9D). This finding
suggests
that potentiation of acid-induced injury by OGD may be due largely to OGD
potentiation of ASIC1-mediated toxicity.
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
23
Aarts et al. (2003) have recently studied ischemia molded by prolonged OGD
(2 hr) but without acidosis. In this model system, they demonstrated
activation of a
Ca2+-permeable nonselective cation conductance activated by reactive
oxygen/nitrogen species resulting in glutamate receptor-independent neuronal
injury.
The prolonged OGD-induced cell injury modeled by Aarts et al. may be reduced
dramatically by agents either scavenging free radicals directly (e.g., trolox)
or
reducing the production of free radicals (e.g., L-NAME) (Aarts et al., 2003).
To
determine whether combined short duration OGD and acidosis induced neuronal
injury may involve a similar mechanism, we tested the effect of trolox and L-
NAME
on OGD/acid-induced LDH release. As shown in Figure 9D, neither trolox (500
pM)
nor L-NAME (300 pM) had significant effect on combined 1 hr OGD/acidosis-
induced
neuronal injury (n = 8-11). Additional experiments demonstrated that the ASIC
blockers amiloride and PcTX venom had no effect on the conductance of TRPM7
channels reported to be responsible for prolonged OGD-induced neuronal injury
by
Aarts et al. (2003) (Supplemental Figure S5 (see website listed above), which
is
incorporated herein by reference). Together, these findings strongly suggest
that
activation of ASICs but not TRPM7 channels may be largely responsible for
combined 1 hr OGD/acidosis-induced neuronal injury in our studies.
7. Activation of ASIC1 a in Ischemic Brain Injury In Vivo
Figure 10 shows data illustrating neuroprotection by ASIC1 blockade and
ASIC1 gene knockout in brain ischemia in vivo. Figure 10A shows a graph of
exemplary data obtained from TTC-stained brain sections illustrating the
stained
volume ("infarct volume") in brains from aCSF (n = 7), amiloride (n =11), or
PcTX
venom (n = 5) injected rats. *p < 0.05 and **p < 0.01 compared with aCSF
injected
group. Figure 10B shows a graph of exemplary data illustrating reduction in
infarct
volume in brains from ASIC1-/- mice (n = 6 for each group). *p < 0.05 and **p
< 0.01
compared with +/+ group. Figure 10C shows a graph of exemplary data
illustrating
reduction in infarct volume in brains from mice i.p. injected with 10 mg/kg
memantine
(Mem) or i.p. injection of memantine accompanied by i.c.v. injection of PcTX
venom
(500 ng/mL). **p < 0.01 compared with aCSF injection and between memantine and
memantine plus PcTX venom (n = 5 in each group). Figure 10D shows a graph of
exemplary data illustrating reduction in infarct volume in brains from either
ASIC1+i+
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
24
(wt) or ASIC1-l- mice i.p. injected with memantine (n = 5 in each group). *p <
0.05,
and**p<0.01.
To provide evidence that activation of ASIC1 a may be involved in ischemic
brain injury in vivo, we first tested the protective effect of amiloride and
PcTX venom
in a rat model of transient focal ischemia (Longa et al., 1989). lschemia (100
min)
was induced by transient middle cerebral artery occlusion (MCAO). A total of 6
pl
artificial CSF (aCSF) alone, aCSF-containing amiloride (1 mM), or PcTX venom
(500
ng/mL) was injected intracerebroventricularly 30 min before and after the
ischemia.
Based on the study by Westergaard (1969), the volume for cerebral ventricular
and
spinal cord fluid for 4-week-old rats is estimated to be -60 ial. Assuming
that the
infused amiloride and PcTX were uniformly distributed in the CSF, we may
expect a
concentration of -100 pM for amiloride and -50 ng/mL for PcTX, which is a
concentration found effective in our cell culture experiments. Infarct volume
was
determined by TTC staining (Bederson et al., 1986) at 24 hr following
ischemia.
Ischemia (100 min) produced an infarct volume of 329.5 25.6 mm3 in aCSF-
injected rats (n = 7) but only 229.7 41.1 mm3 in amiloride-injected (n = 11,
p <
0.05) and 130.4 55.0 mm3 (-60% reduction) in PcTX venom-injected rats (n =
5, p
< 0.01) (Figure 10A).
We next used ASIC1-l- mice to further demonstrate the involvement of
ASIC1a in ischemic brain injury in vivo. Male ASIC1"+, ASIC1+l-, and ASIC1-/-
mice
(-25 g, with congenic C57BI6 background) were subjected to 60 min MCAO as
previously described (Stenzel-Poore et al., 2003). Consistent with the
protection by
pharmacological blockade of ASI C1 a(above), -/- mice displayed significantly
smaller (-61% reduction) infarct volumes (32.9 4.7 mm3, N = 6) as compared
to
+/+ mice (84.6 10.6 mm3, N = 6, p < 0.01). +/- mice also showed reduced
infarct
volume (56.9 6.7 mm3, N 6, p < 0.05) (Figure 10B).
We then determined whether blockade of ASIC1 a channels or knockout of the
ASIC1 gene could provide additional protection in vivo in the setting of
glutamate
receptor blockade. We selected the uncompetitive NMDA receptor antagonist
memantine, as it has been recently used in successful clinical trials (Tariot
et al.,
2004). Memantine (10 mg/kg) was injected intraperitoneally (i.p.) into C57BI6
mice
immediately following 60 min MCAO and accompanied by intracerebroventricular
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
injection (i.c.v.) of a total volume of 0.4 pl aCSF alone or aCSF containing
PcTX
venom (500 ng/mL) 15 min before and following ischemia. In control mice with
i.p.
injection of saline and i.c.v. injection of aCSF, 60 min MCAO induced an
infarct
volume of 123.6 5.3 mm3 (n = 5, Figure 10C). In mice with i.p. injection of
5 memantine and i.c.v. injection of aCSF, the same duration of ischemia
induced an
infarct volume of 73.8 6.9 mm3 (n = 5, p < 0.01). However, in mice injected
with
memantine and PcTX venom, an infarct volume of only 47.0 1.1 mm3 was induced
(n = 5, p < 0.01 compared with both control and memantine groups, Figure 10C).
These data suggest that blockade of homomeric ASIC1a may provide additional
10 protection in in vivo ischemia in the setting of NMDA receptor blockade.
Additional
protection was also observed in ASIC1-l- mice treated with pharmacologic NMDA
blockade (Figure 10D). In ASIC+/} mice i.p. injected with saline or 10 mg/kg
memantine, 60 min MCAO induced an infarct volume of 101.4 9.4 mm3 or 61.6
12.7 mm3, respectively (n = 5 in each group, Figure 10D). However, in ASIC1-/-
mice
15 injected with memantine, the same ischemia duration induced an infarct
volume of
27.7 1.6 mm3 (n = 5), significantly smaller than the infarct volume in
ASIC1+/+ mice
injected with memantine (p < 0.05).
D. Discussion
Despite enormous recent progress defining cellular and molecular responses
20 of the brain to ischemia, there is no effective treatment for stroke
patients. Most
notable are the failures of multicenter clinical trials of glutarnate
antagonists (Lee et
al. 1999 and Wahlgren and Ahmed 2004). Here we demonstrate a new mechanism
of ischemic brain injury and the role of ischemic acidosis in this biology. We
show
that ischemic injury in the setting of acidosis may occur via activation of
Ca2+-
25 permeable ASICs, a newly described class of ligand-gated channels (Waldmann
et
al., 1997a, and Waldmann and Lazdunski, 1998). This Ca2+ toxicity may be
independent of glutamate receptors or voltage-gated Ca2+ channels.
Using whole-cell patch-clamp recording in mixed cortical cultures, we
demonstrate activation of ASIC currents in the range of pHe (extracellular pH)
that
occurs commonly in ischemia. With Fura-2 fluorescent imaging and ion
substitution
protocols, we show ASICs may flux Ca2+ in cortical neurons and may do so in
the
presence of NMDA, AMPA, and voltage-gated Ca2+ channel blockade. Using in
vitro
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
26
cell toxicity models, we demonstrate that acidosis may induce glutamate-
independent neuronal injury, which may be reduced by both nonspecific and
specific
ASIC1 a antagonists, and by lowering [Ca2+]e. In addition, we show that
neurons and
COS-7 cells lacking ASIC1 a may be resistant to acid injury, while
transfection of
COS-7 cells with Ca2+-permeable ASIC1a may result in acid sensitivity. Using
in vivo
focal ischemia models, we demonstrate that pharmacologic blockade of ASIC1 a
channels and ASIC1a gene knockout may both protect the brain from ischemic
injury
and may do so in the presence of NMDA blockade.
Local [H+] may be the agonist for ASICs functioning during normal synaptic
transmission in the brain (Wemmie et al., 2002). This signaling may not be
injurious.
However, ASICs also may respond to the global, marked pH declines that may be
occurring in the ischemic brain. Within 1 min of global ischemia, pHe falls
from 7.2 to
6.5 (Simon et al., 1985), a level that may be sufficient to activate ASIC1 a
channels,
which have a pHo,5 at 6.2. Remarkably, ischemia itself, modeled in vitro,
markedly
may enhance the magnitude of ASIC response at a given level of acidosis, thus
potentiating toxic Ca2+ loading in ischemic neurons. Furthermore, ischemia
dramatically may reduce desensitization of ASIC currents, signifying a
possibility of
long-lasting activity of ASICs during prolonged ischemic acidosis in vivo.
It has been shown in intact animals that brief global reductions of brain pH
to
6.5 alone do not produce brain injury (Litt et al., 1985), nor does hypoxia
alone
(Miyamoto and Auer, 2000, and Pearigen et al., 1996). However, our in vitro
data
suggest that the combination of ischemia (hypoxia) with acidosis (ischemic
acidosis),
as may occur in vivo, may cause marked brain injury through ischemia enhancing
the toxic effect of ASIC1 a channels. This argument is strongly supported by
the
finding that both ASIC1 a blockade and ASIC1 a gene knockout produce
substantial
(-60%) reduction in infarct volume.
Acidosis, apart from affecting ischemic brain injury via ASICs, may affect the
function of other channels as well. Particularly pertinent in ischernia may be
the acid
blockade of the NMDA channels (Tang et al. 1990 and Trayne lis and Cull-Candy
1990), which may be protective against in vitro ischemic neuronal injury (Kaku
et al.
1993 and Giffard et al. 1990). This NMDA blockade in the ischemic brain by
acidosis
might in part explain the failure of NMDA antagonists in human stroke trials.
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
27
Treatment of stroke with ASIC1 a blockade may be particularly effective, as
ischemic
acidosis may be serving as an additional therapy by blocking NMDA function.
As our in vitro studies showing a protective effect of ASIC1 a blockade were
performed in the presence of antagonists of NMDA, AMPA, and voltage-gated Ca2+
channels, the findings reported here may offer a new and robust
neuroprotective
strategy for stroke, either alone or in combination with other therapies (MacG
regor et
al., 2003). Further, we demonstrate in vivo that pharmacologic ASIC1 a
blockade or
ASIC1 a gene deletion may offer more potent neuroprotection against stroke
than
NMDA antagonism.
Together, our studies suggest that activation of Ca2+-permeable ASIC1a may
be a novel, glutamate-independent biological mechanism underlying ischernic
brain
injury. As the regulation of other potentially protective ASIC subunits also
occurs in
the ischemic brain (Johnson et al., 2001), these findings may help the design
of
novel therapeutic neuroprotective strategies for brain ischemia.
E. Experimental Procedures
1. Neuronal Culture
Following anesthesia with halothane, cerebral cortices were dissected from
E16 Swiss mice or P1 ASIC1+/} and ASIC1-/- mice and incubated with 0.05%
trypsin-
EDTA for 10 min at 37 C. Tissues were then triturated with fire-polished glass
pipettes and plated on poly-L-ornithine-coated 24-well plates or 25 x 25 m m
glass
coverslips at a density of 2.5 x 105 cells per well or 106 cells per
coverslip. Neurons
were cultured with MEM supplemented with 10% horse serum (for E16 cultures) or
Neurobasal medium supplemented with B27 (for P1 cultures) and used for
electrophysiology and toxicity studies after 12 days. Glial growth was
suppressed by
addition of 5-fluoro-2-deoxyuridine and uridine, yielding cultured cells with -
90%
neurons as determined by NeuN and GFAP staining (data not shown).
2. Electrophysioloqgy
ASIC currents were recorded with whole-cell patch-clamp and fast-perfusion
techniques. The normal extracellular solution (ECF) contained (in mM) 140 N
aCl, 5.4
KCI, 25 HEPES, 20 glucose, 1.3 CaCI2, 1.0 MgC12, 0.0005 TTX (pH 7.4), 320-335
mOsm. For low pH solutions, various amounts of HCI were added. For solutions
with
pH < 6.0, MES instead of HEPES was used for more reliable pH buffering. Patch
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
28
electrodes contained (in mM) 140 CsF, 2.0 MgCI2, 1.0 CaCI2, 10 HEPES, 11 EGTA,
4 MgATP (pH 7.3), 300 mOsm. The Na+-free solution consisted of 10 mM CaCI2, 25
mM HEPES with equiosmotic NMDG or sucrose substituting for NaCI (Chu et al.,
2002). A multibarrel perfusion system (SF-77B, Warner Instrument Co.) was
employed for rapid exchange of solutions.
3. Cell Injury Assay LDH Measurement
Cells were washed three times with ECF and randomly divided into treatment
groups. MK801 (10 pM), CNQX (20 pM), and nimodipine (5 pM) were added in all
groups to eliminate potential secondary activation of glutamate receptors and
voltage-gated Ca2+ channels. Following acid incubation, neurons were washed
and
incubated in Neurobasal medium at 37 C. LDH release was measured in culture
medium using the LDH assay kit (Roche Molecular Biochemicals). Medium (100 pL)
was transferred from culture wells to 96-well plates and mixed with 100 pL
reaction
solution provided by the kit. Optical density was measured at 492 nm 30 min
later,
utilizing a microplate reader (Spectra Max Plus, Molecular Devices).
Background
absorbance at 620 was subtracted. The maximal releasable LDH was obtained in
each well by 15 min incubation with 1 % Triton X-1 00 at the end of each
experiment.
4. Ca2+ Imaging
Cortical neurons grown on 25 x 25 mm glass coverslips were washed three
times with ECF and incubated with 5 pM fura-2-acetoxymethyl ester for 40 min
at
22 C, washed three times, and incubated in normal ECF for 30 min. Coverslips
were
transferred to a perfusion chamber on an inverted microscope (Nikon TE300).
Cells
were illuminated using a xenon lamp and observed with a 40x UV fluor oil-
immersion
objective lens, and video images were obtained using a cooled CCD camera
(Sensys KAF 1401, Photometrics). Digitized images were acquired and analyzed
in
a PC controlled by Axon Imaging Workbench software (Axon Instruments). The
shutter and filter wheel (Lambda 10-2) were controlled by the software to
allow timed
illumination of cells at 340 or 380 nm excitation wavelengths. Fura-2
fluorescence
was detected at emission wavelength of 510 nm. Ratio images (340/380) were
analyzed by averaging pixel ratio values in circumscribed regions of cells in
the field
of view. The values were exported to SigmaPlot for further analysis.
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
29
5. Fluorescein-Diacetate Staininp and Propidium Iodide Uptake
Cells were incubated in ECF containing fluorescein-diacetate (FDA) (5 pM)
and propidium iodide (PI) (2 pM) for 30 min followed by wash with dye-free
ECF.
Alive (FDA-positive) and dead (PI-positive) cells were viewed and counted on a
microscope (Zeiss) equipped with epifluorescence at 580/630 nm
excitation/emission
for PI and 500/550 nm for FDA. Images were collected using an Optronics DEI-
730
camera equipped with a BQ 8000 sVGA frame grabber and analyzed using
computer software (Bioquant, TN).
6. Transfection of COS-7 Cells
COS-7 cells were cultured in MEM with 10% HS and 1% PenStrep (GIBCO).
At -50% confluence, cells were cotransfected with cDNAs for ASICs and GFP in
pCDNA3 vector using FuGENE6 transfection reagents (Roche Molecular
Biochemicals). DNA for ASICs (0.75 pg) and 0.25 pg of DNA for GFP were used
for
each 35 mm dish. GFP-positive cells were selected for patch-clamp recording 48
hr
after transfection. For stable transfection of ASIC1 a, 500 pg/mL G418 was
added to
culture medium 1 week following the transfection. The surviving G418-resistant
cells
were further plated and passed for >5 passages in the presence of G418. Cells
were
then checked with patch-clamp and immunofluorescent staining for the
expression of
ASIC1 a.
7. Oxygen-Glucose Deprivation
Neurons were washed three times and incubated with glucose-free ECF at pH
7.4 or 6.0 in an anaerobic chamber (Model 1025, Forma Scientific) with an
atmosphere of 85% N2, 10% H2, and 5% CO2 at 35 C. Oxygen-glucose deprivation
(OGD) was terminated after 1 hr by replacing the glucose-free ECF with
Neurobasal
medium and incubating the cultures in a normal cell culture incubator. With
HEPES-
buffered ECF used, 1 hr OGD slightly reduced pH from 7.38 to 7.28 (n = 3) and
from
6.0 to 5.96 (n = 4).
8. Focallschemia
Transient focal ischemia was induced by suture occlusion of the middle
cerebral artery (MCAO) in male rats (SD, 250-300 g) and mice (with congenic
C57B16 background, -25 g) anesthetized using 1.5% isoflurane, 70% N20, and
28.5% 02 with intubation and ventilation. Rectal and temporalis muscle
temperature
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
was maintained at 37 C 0.5 C with a thermostatically controlled heating pad
and
lamp. Cerebral blood flow was monitored by transcranical LASER doppler.
Animals
with blood flow not reduced below 20% were excluded.
Animals were killed with chloral hydrate 24 hr after ischemia. Brains were
5 rapidly removed, sectioned coronally at 1 mm (mice) or 2 mm (rats)
intervals, and
stained by immersion in vital dye (2%) 2,3,5-triphenyltetrazolium
hydrochloride
(TTC). Infarction area was calculated by subtracting the normal area stained
with
TTC in the ischemic hemisphere from the area of the nonischemic hemisphere.
Infarct volume was calculated by summing infarction areas of all sections and
10 multiplying by slice thickness. Rat intraventricular injection was
performed by
stereotaxic technique using a microsyringe pump with cannula inserted
stereotactically at 0.8 mm posterior to bregma, 1.5 mm lateral to midline, and
3.8 mm
ventral to the dura. All manipulations and analyses were performed by
individuals
blinded to treatment groups.
15 F. References
Aarts, M., lihara, K., Wei, W.L., Xiong, Z.G., Arundine, M., Cerwinski, W.,
MacDonald, J.F. and Tymianski, M., 2003. A key role for TRPM7 channels in
anoxic
neuronal death. Cell 115, pp. 863-877.
Akopian, A.N., Chen, C.C., Ding, Y., Cesare, P. and Wood, J.N., 2000. A new
20 member of the acid-sensing ion channel family. Neuroreport 11, pp. 2217-
2222.
Allen, N.J. and Attwell, D., 2002. Modulation of ASIC channels in rat
cerebellar Purkinje neurons by ischemia-related signals. J. Physiol. 543, pp.
521-
529.
Alvarez de Ia Rosa, D., Zhang, P., Shao, D., White, F. and Canessa, C.M.,
25 2002. Functional implications of the localization and activity of acid-
sensitive
channels in rat peripheral nervous system. Proc. Natl. Acad. Sci. USA 99, pp.
2326-
2331.
Alvarez de Ia Rosa, D., Krueger, S.R., Kolar, A., Shao, D., Fitzsimonds, R.M.
and Canessa, C.M., 2003. Distribution, subcellular localization and ontogeny
of
30 ASIC1 in the mammalian central nervous system. J. Physiol. 546, pp. 77-87.
Bassilana, F., Champigny, G., Waldmann, R., De Weille, J.R., Heurteaux, C.
and Lazdunski, M., 1997. The acid-sensitive ionic channel subunit ASIC and the
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
31
mammalian degenerin MDEG form a heteromultimeric H+-gated Na+ channel with
novel properties. J. Biol. Chem. 272, pp. 28819-28822.
Bederson, J.B., Pitts, L.H., Germano, S.M., Nishimura, M.C., Davis, R.L. and
Bartkowski, H.M., 1986. Evaluation of 2,3,5-triphenyltetrazolium chloride as a
stain
for detection and quantification of experimental cerebral infarction in rats.
Stroke 17,
pp. 1304-1308.
Benos, D.J. and Stanton, B.A., 1999. Functional domains within the
degenerin/epithelial sodium channel (Deg/ENaC) superfamily of ion channels. J.
Physiol. 520, pp. 631-644.
Benson, C.J., Eckert, S.P. and McCleskey, E.W., 1999. Acid-evoked currents
in cardiac sensory neurons: a possible mediator of myocardial ischemic
sensation.
Circ. Res. 84, pp. 921-928.
Bevan, S. and Yeats, J., 1991. Protons activate a cation conductance in a
sub-population of rat dorsal root ganglion neurones. J. Physiol. 433, pp. 145-
161.
Bianchi, L. and Driscoll, M., 2002. Protons at the gate: DEG/ENaC ion
channels help us feel and remember. Neuron 34, pp. 337-340.
Chen, C.C., England, S., Akopian, A.N. and Wood, J.N., 1998. A sensory
neuron-specific, proton-gated ion channel. Proc. Natl. Acad. Sci. USA 95, pp.
10240-10245.
Chen, C.C., Zimmer, A., Sun, W.H., Hall, J., Brownstein, M.J. and Zimmer, A.,
2002. A role for ASIC3 in the modulation of high-intensity pain stimuli. Proc.
Natl.
Acad. Sci. USA 99, pp. 8992-8997.
Choi, D.W., 1988. Calcium-mediated neurotoxicity: relationship to specific
channel types and role in ischemic damage. Trends Neurosci. 11, pp. 465-469 a.
Choi, D.W., 1988. Glutamate neurotoxicity and diseases of the nervous
system. Neuron 1, pp. 623-634 b.
Choi, D.W., 1995. Calcium: still center-stage in hypoxic-ischemic neuronal
death. Trends Neurosci. 18, pp. 58-60.
Chu, X.P., Miesch, J., Johnson, M., Root, L., Zhu, X.M., Chen, D., Simon,
R.P. and Xiong, Z.G., 2002. Proton-gated channels in PC12 cells. J.
Neurophysiol.
87, pp. 2555-2561.
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
32
Dingledine, R., Borges, K., Bowie, D. and Traynelis, S.F., 1999. The
glutamate receptor ion channels. Pharmacol. Rev. 51, pp. 7-61.
Escoubas, P., De Weille, J.R., Lecoq, A., Diochot, S., Waldmann, R.,
Champigny, G., Moinier, D., Menez, A. and Lazdunski, M., 2000. Isolation of a
tarantula toxin specific for a class of proton-gated Na+ channels. J. Biol.
Chem. 275,
pp. 25116-25121.
Giffard, R.G., Monyer, H., Christine, C.W. and Choi, D.W., 1990. Acidosis
reduces NMDA receptor activation, glutamate neurotoxicity, and oxygen-glucose
deprivation neuronal injury in cortical cultures. Brain Res. 506, pp. 339-342.
Goldberg, M.P. and Choi, D.W., 1993. Combined oxygen and glucose
deprivation in cortical cell culture: calcium-dependent and calcium-
independent
mechanisms of neuronal injury. J. Neurosci. 13, pp. 3510-3524.
Grunder, S., Geissler, H.S., Bassler, E.L. and Ruppersberg, J.P., 2000. A new
member of acid-sensing ion channels from pituitary gland. Neuroreport 11, pp.
1607-1611.
Immke, D.C. and McCleskey, E.W., 2001. Lactate enhances the acid-sensing
Na+ channel on ischemia-sensing neurons. Nat. Neurosci. 4, pp. 869-870.
Jia, Z., Agopyan, N., Miu, P., Xiong, Z., Henderson, J., Gerlai, R., Taverna,
F.A., Velumian, A., MacDonald, J., Carlen, P. et al., 1996. Enhanced LTP in
mice
deficient in the AMPA receptor GluR2. Neuron 17, pp. 945-956.
Johnson, M.B., Jin, K., Minami, M., Chen, D. and Simon, R.P., 2001. Global
ischemia induces expression of acid-sensing ion channel 2a in rat brain. J.
Cereb.
Blood Flow Metab. 21, pp. 734-740.
Kaku, D.A., Goldberg, M.P. and Choi, D.W., 1991. Antagonism of non-NMDA
receptors augments the neuroprotective effect of NMDA receptor blockade in
cortical
cultures subjected to prolonged deprivation of oxygen and glucose. Brain Res.
554,
pp. 344-347.
Kaku, D.A., Giffard, R.G. and Choi, D.W., 1993. Neuroprotective effects of
glutamate antagonists and extracellular acidity. Science 260, pp. 1516-1518.
Koh, J.Y. and Choi, D.W., 1987. Quantitative determination of glutamate
mediated cortical neuronal injury in cell culture by lactate dehydrogenase
efflux
assay. J. Neurosci. Methods 20, pp. 83-90.
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
33
Krishtal, 0., 2003. The ASICs: signaling molecules?. Modulators? Trends
Neurosci. 26, pp. 477-483.
Krishtal, O.A. and Pidoplichko, V.I., 1981. A receptor for protons in the
membrane of sensory neurons may participate in nociception. Neuroscience 6,
pp.
2599-2601.
Lee, J.M., Zipfel, G.J. and Choi, D.W., 1999. The changing landscape of
ischaemic brain injury mechanisms. Nature Suppl. 399, pp. A7-14.
Lingueglia, E., De Weille, J.R., Bassilana, F., Heurteaux, C., Sakai, H.,
Waldmann, R. and Lazdunski, M., 1997. A modulatory subunit of acid sensing ion
channels in brain and dorsal root ganglion cells. J. Biol. Chem. 272, pp.
29778-
29783.
Litt, L., Gonzalez-Mendez, R., Severinghaus, J.W., Hamilton, W.K.,
Shuleshko, J., Murphy-Boesch, J. and James, T.L., 1985. Cerebral intracellular
changes during supercarbia: an in vivo 31 P nuclear magnetic resonance study
in
rats. J. Cereb. Blood Flow Metab. 5, pp. 537-544.
Longa, E.Z., Weinstein, P.R., Carlson, S. and Cummins, R., 1989. Reversible
middle cerebral artery occlusion without craniectomy in rats. Stroke 20, pp.
84-91.
MacGregor, D.G., Avshalumov, M.V. and Rice, M.E., 2003. Brain edema
induced by in vitro ischemia: causal factors and neuroprotection. J.
Neurochem. 85,
pp.1402-1411.
McDonald, J.W., Bhattacharyya, T., Sensi, S.L., Lobner, D., Ying, H.S.,
Canzoniero, L.M. and Choi, D.W., 1998. Extracellular acidity potentiates AMPA
receptor-mediated cortical neuronal death. J. Neurosci. 18, pp. 6290-6299.
McLennan, H., 1983. Receptors for the excitatory amino acids in the
mammalian central nervous system. Prog. Neurobiol. 20, pp. 251-271.
Meldrum, B.S., 1995. Excitatory amino acid receptors and their role in
epilepsy and cerebral ischemia. Ann. N YAcad. Sci. 757, pp. 492-505.
Miyamoto, O. and Auer, R.N., 2000. Hypoxia, hyperoxia, ischemia, and brain
necrosis. Neurology 54, pp. 362-371.
Nedergaard, M., Kraig, R.P., Tanabe, J. and Pulsinelli, W.A., 1991. Dynamics
of interstitial and intracellular pH in evolving brain infarct. Am. J.
Physiol. 260, pp.
R581-R588.
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
34
Pearigen, P., Gwinn, R. and Simon, R.P., 1996. The effects in vivo of hypoxia
on brain injury. Brain Res. 725, pp. 184-191.
Price, M.P., Snyder, P.M. and Welsh, M.J., 1996. Cloning and expression of a
novel human brain Na+ channel. J. Biol. Chem. 271, pp. 7879-7882.
Price, M.P., Lewin, G.R., Mcllwrath, S.L., Cheng, C., Xie, J., Heppenstall,
P.A., Stucky, C.L., Mannsfeldt, A.G., Brennan, T.J., Drummond, H.A. et al.,
2000.
The mammalian sodium channel BNC1 is required for normal touch sensation.
Nature 407, pp. 1007-1011.
Price, M.P., Mcllwrath, S.L., Xie, J., Cheng, C., Qiao, J., Tarr, D.E., Sluka,
K.A., Brennan, T.J., Lewin, G.R. and Welsh, M.J., 2001. The DRASIC cation
channel
contributes to the detection of cutaneous touch and acid stimuli in mice.
Neuron 32,
pp. 1071-1083.
Rehncrona, S., 1985. Brain acidosis. Ann. Emerg. Med. 14, pp. 770-776.
Rothman, S.M. and Olney, J.W., 1986. Glutamate and the pathophysiology of
hypoxic-ischemic brain damage. Ann. Neurol. 19, pp. 105-111.
Sattler, R., Xiong, Z., Lu, W.Y., Hafner, M., MacDonald, J.F. and Tymianski,
M., 1999. Specific coupling of NMDA receptor activation to nitric oxide
neurotoxicity
by PSD-95 protein. Science 284, pp. 1845-1848.
Siesjo, B.K., Katsura, K. and Kristian, T., 1996. Acidosis-related damage.
Adv.
Neurol. 71, pp. 209-233.
Simon, R.P., Swan, J.H., Griffiths, T. and Meldrum, B.S., 1984. Blockade of
N-methyl-D-aspartate receptors may protect against ischemic damage in the
brain.
Science 226, pp. 850-852.
Simon, R.P., Benowitz, N., Hedlund, R. and Copeland, J., 1985. Influence of
the blood-brain pH gradient on brain phenobarbital uptake during status
epilepticus.
J. Pharmacol. Exp. Ther. 234, pp. 830-835.
Sluka, K.A., Price, M.P., Breese, N.M., Stucky, C.L., Wemmie, J.A. and
Welsh, M.J., 2003. Chronic hyperalgesia induced by repeated acid injections in
muscle is abolished by the loss of ASIC3, but not ASIC1. Pain 106, pp. 229-
239.
Stenzel-Poore, M.P., Stevens, S.L., Xiong, Z., Lessov, N.S., Harrington, C.A.,
Mori, M., Meller, R., Rosenzweig, H.L., Tobar, E., Shaw, T.E. et al., 2003.
Effect of
ischaemic preconditioning on genomic response to cerebral ischaemia:
similarity to
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
neuroprotective strategies in hibernation and hypoxia-tolerant states. Lancet
362, pp.
1028-1037.
Swanson, R.A., Farrell, K. and Simon, R.P., 1995. Acidosis causes failure of
astrocyte glutamate uptake during hypoxia. J. Cereb. Blood Flow Metab. 15, pp.
5 417-424.
Tang, C.M., Dichter, M. and Morad, M., 1990. Modulation of the N-methyl-D-
aspartate channel by extracellular H+. Proc. Natl. Acad. Sci. USA 87, pp. 6445-
6449.
Tariot, P.N., Farlow, M.R., Grossberg, G.T., Graham, S.M., McDonald, S. and
10 Gergel, I., 2004. Memantine treatment in patients with moderate to severe
Alzheimer
disease already receiving donepezil: a randomized controlled trial. JAMA 291,
pp.
317-324.
Tombaugh, G.C. and Sapolsky, R.M., 1993. Evolving concepts about the role
of acidosis in ischemic neuropathology. J. Neurochem. 61, pp. 793-803.
15 Traynelis, S.F. and. Cull-Candy, S.G., 1990. Proton inhibition of N-methyl-
D-
aspartate receptors in cerebellar neurons. Nature 345, pp. 347-350.
Ugawa, S., Ueda, T., Ishida, Y., Nishigaki, M., Shibata, Y. and Shimada, S.,
2002. Amiloride-blockable acid-sensing ion channels are leading acid sensors
expressed in human nociceptors. J. Clin. Invest. 110, pp. 1185-1190.
20 Varming, T., 1999. Proton-gated ion channels in cultured mouse cortical
neurons. Neurotaharmacology 38, pp. 1875-1881.
Wahlgren, N.G. and Ahmed, N., 2004. Neuroprotection in cerebral ischaemia:
facts and fancies-the need for new approaches. Cerebrovasc. Dis. Supp. 17, pp.
153-166.
25 Waldmann, R. and Lazdunski, M., 1998. H(+)-gated cation channels: neuronal
acid sensors in the NaC/DEG family of ion channels. Curr. Opin. Neurobiol. 8,
pp.
418-424.
Waldmann, R., Champigny, G., Bassilana, F., Heurteaux, C. and Lazdunski,
M., 1997a. A proton-gated cation channel involved in acid-sensing. Nature 386,
pp.
30 173-177.
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
36
Waldmann, R., Bassilana, F., de Weille, J., Champigny, G., Heurteaux, C. and
Lazdunski, M., 1997b. Molecular cloning of a non-inactivating proton-gated Na+
channel specific for sensory neurons. J. Biol. Chem. 272, pp. 20975-20978.
Waldmann, R., Champigny, G., Lingueglia, E., De Weille, J., Heurteaux, C.
and Lazdunski, M., 1999. H(-t-)-gated cation channels. Ann. N Y Acad. Sci.
868, pp.
67-76.
Wemmie, J.A., Chen, J., Askwith, C.C., Hruska-Hageman, A.M., Price, M.P.,
Nolan, B.C., Yoder, P.G., Lamani, E., Hoshi, T., Freeman, J.H. and Welsh,
M.J.,
2002. The acid-activated ion channel ASIC contributes to synaptic plasticity,
learning, and memory. Neuron 34, pp. 463-477.
Wemmie, J.A., Askwith, C.C., Lamani, E., Cassell, M.D., Freeman Jr., J.H.
and Welsh, M.J., 2003. Acid-sensing ion channel 1 is localized in brain
regions with
high synaptic density and contributes to fear conditioning. J. Neurosci. 23,
pp. 5496-
5502.
Westergaard, E., 1969_ The cerebral ventricles of the rat during growth. Acta
Anat. (Basel) 74, pp. 405-423 _
Xiong, Z., Lu, W. and MacDonald, J.F., 1997. Extracellular calcium sensed by
a novel cation channel in hippocampal neurons. Proc. Natl. Acad. Sci. USA 94,
pp.
7012-7017.
Yermolaieva, 0., Leonard, A.S., Schnizler, M.K., Abboud, F.M. and Welsh,
M.J., 2004. Extracellular acidosis increases neuronal cell calcium by
activating acid-
sensing ion channel 1 a. Proc. Natl. Acad. Sci. USA 101, pp. 6752-6757.
Ying, W., Han, S.K., Miller, J.W. and Swanson, R.A., 1999. Acidosis
potentiates oxidative neuronal death by multiple mechanisms. J. Neurochem. 73,
pp.
1549-1556.
Example 2: Time Window of PcTX Neuroprotection
This example describes exemplary experiments that measure the
neuroprotective effect of PcTX venom at different times after onset of stroke
in
rodents; see Figure 11. Brain ischemia (stroke) was induced in rodents by mid-
cerebral artery occlusion (MCAO). At the indicated times after induction,
artificial
cerebrospinal fluid (aCSF), PcTX venom (0.5 pL, 500 ng/mL total protein), or
inactivated (boiled) venom was infused into the lateral ventricles of each
rodent.
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
37
Administration of PcTX venom provided a 60% reduction in stroke volume both at
one hour and at three hours after stroke onset. Furthermore, substantial
stroke
volume reduction still may be maintained if treatment is withheld for five
hours after
the onset of the MCAO. Accordingly, neuroprotection due to ASIC inhibition may
have an extended therapeutic time window after stroke onset, allowing stroke
subjects to benefit from treatment performed hours after the stroke began.
This
effect of ASIC blockade on stroke neuroprotection is far more robust than that
of
calcium channel blockade of the NMDA receptor (a major target for experimental
stroke therapeutics) using a glutamate antagonist. No glutamate antagonist,
thus far,
has such a favorable profile as shown here for ASIC1 a-selective inhibition.
Example 3: Exemplary Cystine Knot Peptides
This example describes exemplary cystine knot peptides, including full-length
PcTxl and deletion derivatives of PcTx, which may be screened in cultured
cells,
tested in ischemic animals (e.g., rodents such as mice or rats), and/or
administered
to ischemic human subjects; see Figures 12 and 13.
Figure 12 shows the primary amino acid sequence (SEQ ID NO:1), in one-
letter code, of an exemplary cystine knot peptide, PcTxl, indicated at 50,
with
various exemplary peptide features shown relative to amino acid positions 1-
40.
Peptide 50 may include six cysteine residues that form cystine bonds 52, 54,
56 to
create a cystine knot motif 58. The peptide also may include one or more beta
sheet
regions 60 and a positively charged region 62. An N-terminal region 64 and a C-
terminal region 66 may flank the cystine knot motif.
Figure 13 shows a comparison of the PcTxl peptide 50 of Figure 12 aligned
with various exemplary deletion derivatives of the peptide. These derivatives
may
include an N-terminal deletion 70 (SEQ ID NO:2), a partial C-terminal deletion
72
(SEQ ID NO:3), a full C-terminal deletion 74 (SEQ ID NO:4), and an N/C
terminal
deletion 76 (SEQ ID NO:5). Other derivatives of PcTxl may include any
deletion,
insertion, or substitution of one or more amino acids, for example, while
maintaining
sequence similarity or identity of at least about 25% or about 50% with the
original
PcTxl sequence.
Each PcTxl derivative may be tested for its ability to inhibit ASIC proteins
selectively and/or for an effect, if any, on ischemia. Any suitable test
system(s) may
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
38
be used to perform this testing including any of the cell-based assay systems
and/or
animal model systems described elsewhere in the present teachings. The PcTxl
derivative also or alternatively may be tested in ischemic human subjects.
Example 4: Selectivity of PcTX Venom for ASIC1a
This example describes experiments that measure the selectivity of PcTX
venom (and thus PcTxl toxin) for ASIC1 a alone, relative to other ASIC
proteins or
combinations of ASIC proteins expressed in cultured cells; see Figure 14. COS-
7
cells expressing the indicated ASIC proteins were treated vvith PcTX venom (25
ng/mL on ASIC1a expressing cells and 500 ng/mL on ASIC2a, ASIC3 or ASIC1a+2a
expressing cells). Channel currents were measured at the pH of half maximal
channel activation (pH 0.5). PcTX venom largely blocked the currents mediated
by
ASIC1 a homomeric channels at a protein concentration of 25 ng/mL, with no
effect
on the currents mediated by homomeric ASIC2a, ASIC3, or heteromeric
ASIC1 a/ASIC2a at 500 ng/mL (n = 3-6, Figure 14). At 500 ng/mL, PcTX venom
also
did not affect the currents mediated by other ligand-gated channels (e.g. NMDA
and
GABA receptor-gated channels) and voltage-gated channels (e.g. Na+, Ca2+, and
K+ channels) (n = 4-5). These experiments indicate that PcTX venom and thus
PcTx1 peptide is a specific blocker for homomeric ASIC1 a. Using this cell-
based
assay system, the potency and selectivity of ASIC inhibition rnay be measured
for
various synthetic peptides or other candidate inhibitors (e.g., see Example
3).
Example 5: Nasal Administration of PcTX Venom is Neuroprotective
This example describes exemplary data indicating the efficacy of nasally
administered PcTX venom for reducing ischemia-induced injury in an animal
model
system of stroke; see Figure 15. Cerebral ischemia was induced in male mice by
mid-cerebral artery occlusion. One hour after occlusion was initiated animals
were
treated as controls or were treated with PcTX venom (50pL of 5 ng/mL (total
protein)
PcTx venom introduced intranasally). Nasal administration of PcTX venom
resulted
in a 55% reduction in ischemia-induced injury (ischemic darnage), as defined
by
infarct volume, relative to control treatment. Nasal administration may be via
a spray
that is deposited substantially in the,nasal passages rather than inhaled into
the
lungs and/or may be via an aerosol that is at least partially inhaled into the
lungs. In
some examples, nasal administration may have a number of advantages over other
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
39
routes of administration, such as more efficient delivery to the brain and/or
adaptability for self-administration by an ischemic subject.
Example 6: Selected Embodiments
This example describes selected embodiments of the present teachings,
presented as a series of indexed paragraphs.
1. A method for the treatment of ischemia-induced injury, comprising:
administering a therapeutically effective amount of an inhibitor of an acid
sensing ion channel (ASIC) family member to a subject in need thereof.
2. The method of paragraph 1, wherein the step of administering is
performed on a stroke patient.
3. The method of paragraph 1, wherein the step of administering is
performed based on a risk of the subject for a future ischemic episode or
based or
due to chronic ischemia.
4. The method of paragraph 1, wherein the step of administering is
performed to treat injury induced by ischemic heart disease.
5. The method of paragraph 1, wherein the step of administering i ncludes
administering a plurality of doses of the inhibitor to the subject at
different times.
6. The method of paragraph 1, wherein the step of administering is
performed by injection of the inhibitor.
7. The method of paragraph 1, wherein the step of administering is
performed by ingesting or breathing the inhibitor.
8. The method of paragraph 1, wherein the step of administering includes
administering an inhibitor of ASIC1 family members.
9. The method of paragraph 8, wherein the step of administering includes
administering an inhibitor that is selective for ASIC1 family members relative
to other
ASIC family members.
10. The method of paragraph 1, wherein the step of administering includes
administering an inhibitor of ASIC1 a.
11. The method of paragraph 10, wherein the step of administering
includes administering an inhibitor that is selective for ASIC1a relative to
other ASIC
family members.
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
12. The method of paragraph 11, wherein the step of administering
includes administering an inhibitor that is specific for ASIC1 a relative to
other ASIC
family members.
13. The method of paragraph 1, wherein the step of administering includes
5 administering a peptide having a cystine knot motif.
14. The method of paragraph 13, wherein the step of administering
includes administering PcTxl, a toxin peptide from a tarantula species.
15. A method of screening for drugs to treat ischemia-induced injury,
comprising:
10 selecting an assay system for measuring interaction with ASIC1 a;
testing a set of compounds for interaction with ASIC1 a in the assay system to
identify at least one compound that shows interaction;
administering the at least one compound, or a structural relative thereof, to
a
subject with ischemia to test the efficacy of the at least one compound or the
15 structural relative for treatment of ischemia-induced injury.
16. The method of paragraph 15, wherein the step of selecting an assay
system includes selecting an assay system that measures ion flux mediated by
ASIC1 a.
17. The method of paragraph 16, wherein the step of selecting an assay
20 system includes selecting an assay system that measures flux of calcium
mediated
by ASIC1 a.
18. The method of paragraph 16, wherein the step of testing a set of
compounds includes testing the compounds for inhibition of the ion flux.
19. The method of paragraph 15, wherein the step of testing a set of
25 compounds includes a step of testing the set of compounds for selective or
specific
inhibition of ASIC1 a relative to at least one other ASIC family member.
20. A composition for treating ischemia-induced injury, comprising:
an ASIC1 a inhibitor configured as a medicament for administration to human
subjects.
30 21. The composition of paragraph 20, wherein the ASIC1 a inhibitor is
selective or specific for ASIC1 a relative to each other ASIC family member.
CA 02622890 2008-03-17
WO 2006/034035 PCT/US2005/033171
41
22. The composition of paragraph 20, wherein the ASIC1 a inhibitor is a
peptide having a cystine knot motif.
23. The composition of paragraph 22, wherein the peptide is PcTxl, a toxin
from a tarantula species.
The disclosure set forth above may encompass one or more distinct
inventions, with independent utility. Each of these inventions has been
disclosed in
its preferred form(s). These preferred forms, including the specific
embodiments
thereof as disclosed and illustrated herein, are not intended to be considered
in a
limiting sense, because numerous variations are possible. The subject matter
of the
inventions includes all novel and nonobvious combinations and subcombinations
of
the various elements, features, functions, and/or properties disclosed herein.
The
following claims particularly point out certain combinations and
subcombinations
regarded as novel and nonobvious. Inventions embodied in other combinations
and
subcombinations of features, functions, elements, and/or properties may be
claimed
in applications claiming priority from this or a related application. Such
claims,
whether directed to a different invention or to the same invention, and
whether
broader, narrower, equal, or different in scope to the original claims, also
are
regarded as included within the subject matter of the inventions of the
present
disclosure.
